Islamabad: GlaxoSmithKline Consumer Healthcare Pakistan Ltd announced on Saturday that we are continued to manufacture and supply Panadol products for ailing masses and also made it clear that the rationale behind our action to declare Force Majeure on the production of our Panadol range is due to an increase the cost of production of Paracetamol raw ingredients.
According to press release issued by GSK, that we have been an integral part of the health sector for many years and contributing to the economic growth and stability of Pakistan with our products and local manufacturing footprint.
Few weeks ago, a number of factors have contributed to reduced availability of Panadol. Most prominently, the price of Paracetamol (an active pharmaceutical ingredient) has increased in both international and domestic markets.
HE add that this has forced many brands across the pain relief analgesics category to either reduce volume or close down production in Pakistan. Despite these challenges, we have continued to manufacture and supply Panadol, they added.
As written to a letter to the Pakistani Government, it is no longer viable for us to continue in this way, until action is taken to rationalize pricing.
Unfortunately, we are declaring force majeure regarding the production of Panadol tablets, Panadol Extra tablets and children’s Panadol liquid range. Despite our exhausted efforts to mitigate this matter, the situation is now beyond our control.
We are hoping that the government addresses this critical situation so that we can continue to deliver better healthcare services to Pakistanis.
Comments are closed, but trackbacks and pingbacks are open.